Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 15/20 | 0.78 |
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17362448 | 0.99 | MKNK1 (0.77) | MKNK1MKNK2 | |
| SCHEMBL17363017 | 0.90 | MKNK1 (0.69) | MKNK1MKNK2 | |
| SCHEMBL17369328 | 0.88 | MKNK1 (0.82) | MKNK1MKNK2 | |
| SCHEMBL17369295 | 0.88 | MKNK2 (1.00) | MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL17362529 | 0.87 | MKNK1 (0.81) | MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL17362912 | 0.87 | MKNK2 (0.98) | MKNK1MKNK2 | |
| SCHEMBL17369312 | 0.86 | MKNK2 (0.82) | MKNK1MKNK2 | |
| SCHEMBL17369325 | 0.85 | MKNK1 (0.78) | MKNK1MKNK2 | |
| SCHEMBL17369326 | 0.85 | MKNK1 (0.78) | MKNK1MKNK2 | |
| SCHEMBL17362630 | 0.85 | MKNK1 (0.78) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (NL) | 2018-03-29 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | MKNK1 75/4885MKNK2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.